The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer

British Journal of Haematology

Volumn 179, Issue 1, 2017, Pages 20-35

  Flynn, Michael J ^a   Hartley, John A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

anti CD25 targeted therapy; CD25; CD25 expressing malignancies; interleukin 2 receptor; regulatory T cells

Indexed keywords

BASILIXIMAB; DACLIZUMAB; DENILEUKIN DIFTITOX; E 7777; IMMUNOMODULATING AGENT; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 131; RECOMBINANT IMMUNOTOXIN; RECOMBINANT INTERLEUKIN 2; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; CELL SURFACE; CELLS BY BODY ANATOMY; CELLULAR IMMUNITY; CUTANEOUS T CELL LYMPHOMA; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASM; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN SECRETION; RADIOIMMUNOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE ACTIVATION; UPREGULATION; UVEITIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 85019663404     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14770     Document Type: Review

References (125)

1. Alvaro, T., Lejeune, M., Salvado, M.T., Bosch, R., Garcia, J.F., Jaen, J., Banham, A.H., Roncador, G., Montalban, C. & Piris, M.A. (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clinical Cancer Research, 11, 1467–1473.
2. Alvaro, T., Lejeune, M., Escriva, P., Pons, L.E., Bosch, R., Jaen, J., Lopez, C., Salvado, M.T. & de Sanjose, S. (2009) Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Critical Reviews in Oncology Hematology, 70, 103–113.
3. Ambrosetti, A., Nadali, G., Vinante, F., Ricetti, M.M., Todeschini, G., Morosato, L., De Sabata, D., Bergamo Andreis, I.A., Chilosi, M., Semenzato, G. & Pizzolo, G. (1993) Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease. International Journal of Clinical and Laboratory Research, 23, 34–37.
4. Arce Vargas, F., Furness, A.J.S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., Ben Aissa, A., Franz, D., Werner Sunderland, M., Wong, Y.N.S., Henry, J.Y., O'Brien, T., Nicol, D., Challacombe, B., Beers, S.A.; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic, S., Gore, M., Larkin, J., Swanton, C., Chester, K.A., Pule, M., Ravetch, J.V., Marafioti, T., Peggs, K.S. & Quezada, S.A. (2017) Fc-optimized Anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity, 46, 577–586.
5. Armstrong, S.A. & Look, A.T. (2005) Molecular genetics of acute lymphoblastic leukemia. Journal of Clinical Oncology, 23, 6306–6315.
6. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L. & Rosenberg, S.A. (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. Journal of Immunotherapy, 28, 582–592.
7. +CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106, 2018–2025.
8. Bien, E. & Balcerska, A. (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13, 1–26.
9. Boyman, O. & Sprent, J. (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology, 12, 180–190.
10. Boyman, O., Surh, C.D. & Sprent, J. (2006) Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opinion on Biological Therapy, 6, 1323–1331.
11. Cabrera, R., Ararat, M., Eksioglu, E.A., Cao, M., Xu, Y., Wasserfall, C., Atkinson, M.A., Liu, C. & Nelson, D.R. (2010) Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. Scandinavian Journal of Immunology, 72, 293–301.
12. Camisaschi, C., Tazzari, M., Rivoltini, L. & Castelli, C. (2014) Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients. Methods in Molecular Biology, 1139, 201–221.
13. Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S.H., Forman, S.J. & Kane, S.E. (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Molecular Cancer Therapeutics, 14, 1376–1384.
14. Church, A.C. (2003) Clinical advances in therapies targeting the interleukin-2 receptor. QJM, 96, 91–102.
15. Dancey, G., Violet, J., Malaroda, A., Green, A.J., Sharma, S.K., Francis, R., Othman, S., Parker, S., Buscombe, J., Griffin, N., Chan, P.S., Malhotra, A., Woodward, N., Ramsay, A., Ross, P., Lister, T.A., Amlot, P., Begent, R. & McNamara, C. (2009) A phase I clinical trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clinical Cancer Research, 15, 7701–7710.
16. Decarvalho, S., Rand, H.J. & Lewis, A. (1964) Coupling of cyclic chemotherapeutic compounds to immune gamma-globulins. Nature, 202, 255–258.
17. Duvic, M., Kuzel, T.M., Dang, N.H., Prince, M., Feldman, T., Foss, F.M., Guo, M., Ottesen, L.H., Ooi, C.E. & Kim, Y.H. (2014) A dose finding lead-in study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in persistent or recurrent Cutaneous T-Cell Lymphoma (CTCL). Blood, 124, 3097.
18. Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, M.T., Drillich, S., Schon, G., Bohlen, H., Tesch, H., Hansmann, M.L., Barth, S., Schindler, J., Ghetie, V., Uhr, J. & Vitetta, E. (1997) A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89, 403–410.
19. Farinha, P., Al-Tourah, A., Gill, K., Klasa, R., Connors, J.M. & Gascoyne, R.D. (2010) The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood, 115, 289–295.
20. Flynn, M.J., Zammarchi, F., Tyrer, P.C., Akarca, A.U., Janghra, N., Britten, C.E., Havenith, C.E., Levy, J.N., Tiberghien, A., Masterson, L.A., Barry, C., D'Hooge, F., Marafioti, T., Parren, P.W., Williams, D.G., Howard, P.W., van Berkel, P.H. & Hartley, J.A. (2016) ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) targeting CD25-expressing hematological malignancies. Molecular Cancer Therapeutics, 15, 2709–2721.
21. Geng, H., Brennan, S., Milne, T.A., Chen, W.Y., Li, Y., Hurtz, C., Kweon, S.M., Zickl, L., Shojaee, S., Neuberg, D., Huang, C., Biswas, D., Xin, Y., Racevskis, J., Ketterling, R.P., Luger, S.M., Lazarus, H., Tallman, M.S., Rowe, J.M., Litzow, M.R., Guzman, M.L., Allis, C.D., Roeder, R.G., Muschen, M., Paietta, E., Elemento, O. & Melnick, A.M. (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discovery, 2, 1004–1023.
22. Gerber, H.P., Sapra, P., Loganzo, F. & May, C. (2016) Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochemical Pharmacology, 102, 1–6.
23. Giannopoulos, K., Schmitt, M., Kowal, M., Wlasiuk, P., Bojarska-Junak, A., Chen, J., Rolinski, J. & Dmoszynska, A. (2008) Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncology Reports, 20, 677–682.
24. Glowala-Kosinska, M., Chwieduk, A., Nieckula, J., Sadus-Wojciechowska, M., Grosicki, S., Rusin, A., Nowara, E. & Giebel, S. (2013) Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. European Journal of Haematology, 91, 122–128.
25. Goebel, J., Stevens, E., Forrest, K. & Roszman, T.L. (2000) Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transplant Immunology, 8, 153–159.
26. de Goer de Herve, M.G., Gonzales, E., Hendel-Chavez, H., Decline, J.L., Mourier, O., Abbed, K., Jacquemin, E. & Taoufik, Y. (2010) CD25 appears non essential for human peripheral T(reg) maintenance in vivo. PLoS ONE, 5, e11784.
27. Gonen, M., Sun, Z., Figueroa, M.E., Patel, J.P., Abdel-Wahab, O., Racevskis, J., Ketterling, R.P., Fernandez, H., Rowe, J.M., Tallman, M.S., Melnick, A., Levine, R.L. & Paietta, E. (2012) CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 120, 2297–2306.
28. Gooding, R., Riches, P., Dadian, G., Moore, J. & Gore, M. (1995) Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. British Journal of Cancer, 72, 452–455.
29. Grygorowicz, M.A., Biernacka, M., Bujko, M., Nowak, E., Rymkiewicz, G., Paszkiewicz-Kozik, E., Borycka, I.S., Bystydzienski, Z., Walewski, J. & Markowicz, S. (2016) Human regulatory T cells suppress proliferation of B lymphoma cells. Leukaemia & Lymphoma, 57, 1903–1920.
30. + anaplastic large cell lymphoma in children. American Journal of Clinical Pathology, 132, 28–33.
31. Guo, Z., Wang, A., Zhang, W., Levit, M., Gao, Q., Barberis, C., Tabart, M., Zhang, J., Hoffmann, D., Wiederschain, D., Rocnik, J., Sun, F., Murtie, J., Lengauer, C., Gross, S., Zhang, B., Cheng, H., Patel, V., Schio, L., Adrian, F., Dorsch, M., Garcia-Echeverria, C. & Huang, S.M. (2014) PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood, 124, 1777–1789.
32. Hannani, D., Vetizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., Mateus, C., Allison, J.P., Ribas, A., Wolchok, J.D., Yuan, J., Wong, P., Postow, M., Mackiewicz, A., Mackiewicz, J., Schadendorff, D., Jaeger, D., Zornig, I., Hassel, J., Korman, A.J., Bahjat, K., Maio, M., Calabro, L., Teng, M.W., Smyth, M.J., Eggermont, A., Robert, C., Kroemer, G. & Zitvogel, L. (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 25, 208–224.
33. Hartley, J.A., Spanswick, V.J., Brooks, N., Clingen, P.H., McHugh, P.J., Hochhauser, D., Pedley, R.B., Kelland, L.R., Alley, M.C., Schultz, R., Hollingshead, M.G., Schweikart, K.M., Tomaszewski, J.E., Sausville, E.A., Gregson, S.J., Howard, P.W. & Thurston, D.E. (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Research, 64, 6693–6699.
34. Hashimoto, Y., Yokohama, A., Saitoh, A., Nakahashi, H., Toyama, K., Mitsui, T., Koiso, H., Saitoh, T., Handa, H., Uchiumi, H., Jinbo, T., Murayama, K., Matsumoto, M., Sawamura, M., Karasawa, M., Murakami, H., Hirato, J., Nojima, Y., Kojima, M. & Tsukamoto, N. (2013) Prognostic importance of the soluble form of IL-2 receptoralpha (sIL-2Ralpha) and its relationship with surface expression of IL-2Ralpha (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. Journal of Clinical and Experimental Hematopathology, 53, 197–205.
35. Hayden, A., Park, S., Giustini, D., Lee, A.Y. & Chen, L.Y. (2016) Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Reviews, 30, 411–420.
36. Herrmann, F., Cannistra, S.A., Levine, H. & Griffin, J.D. (1985) Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. Journal of Experimental Medicine, 162, 1111–1116.
37. + regulatory T cells. The Journal of Immunology, 177, 2186–2194.
38. Holter, W., Goldman, C.K., Casabo, L., Nelson, D.L., Greene, W.C. & Waldmann, T.A. (1987) Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. The Journal of Immunology, 138, 2917–2922.
39. Horiuchi, S., Koyanagi, Y., Tanaka, Y., Waki, M., Matsumoto, A., Zhou, Y.W., Yamamoto, M. & Yamamoto, N. (1997) Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Immunology, 91, 28–34.
40. Huss, D.J., Mehta, D.S., Sharma, A., You, X., Riester, K.A., Sheridan, J.P., Amaravadi, L.S., Elkins, J.S. & Fontenot, J.D. (2015) In vivo maintenance of human regulatory T cells during CD25 blockade. The Journal of Immunology, 194, 84–92.
41. Jacobs, J.F., Punt, C.J., Lesterhuis, W.J., Sutmuller, R.P., Brouwer, H.M., Scharenborg, N.M., Klasen, I.S., Hilbrands, L.B., Figdor, C.G., de Vries, I.J. & Adema, G.J. (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clinical Cancer Research, 16, 5067–5078.
42. Janik, J.E., Morris, J.C., O'Mahony, D., Pittaluga, S., Jaffe, E.S., Redon, C.E., Bonner, W.M., Brechbiel, M.W., Paik, C.H., Whatley, M., Chen, C., Lee, J.H., Fleisher, T.A., Brown, M., White, J.D., Stewart, D.M., Fioravanti, S., Lee, C.C., Goldman, C.K., Bryant, B.R., Junghans, R.P., Carrasquillo, J.A., Worthy, T., Corcoran, E., Conlon, K.C. & Waldmann, T.A. (2015) 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 112, 13045–13050.
43. Junghans, R.P. & Waldmann, T.A. (1996) Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. Journal of Experimental Medicine, 183, 1587–1602.
44. Katsuya, H., Yamanaka, T., Ishitsuka, K., Utsunomiya, A., Sasaki, H., Hanada, S., Eto, T., Moriuchi, Y., Saburi, Y., Miyahara, M., Sueoka, E., Uike, N., Yoshida, S., Yamashita, K., Tsukasaki, K., Suzushima, H., Ohno, Y., Matsuoka, H., Jo, T., Suzumiya, J. & Tamura, K. (2012) Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. Journal of Clinical Oncology, 30, 1635–1640.
45. Kersseboom, R., Ta, V.B., Zijlstra, A.J., Middendorp, S., Jumaa, H., van Loo, P.F. & Hendriks, R.W. (2006) Bruton's tyrosine kinase and SLP-65 regulate pre-B cell differentiation and the induction of Ig light chain gene rearrangement. The Journal of Immunology, 176, 4543–4552.
46. Klapper, J.A., Downey, S.G., Smith, F.O., Yang, J.C., Hughes, M.S., Kammula, U.S., Sherry, R.M., Royal, R.E., Steinberg, S.M. & Rosenberg, S. (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer, 113, 293–301.
47. Kobayashi, H., Tagaya, Y., Han, E.S., Kim, I.S., Le, N., Paik, C.H., Pastan, I., Nelson, D.L., Waldmann, T.A. & Carrasquillo, J.A. (1999) Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. Cytokine, 11, 1065–1075.
48. Kreitman, R.J., Wilson, W.H., White, J.D., Stetler-Stevenson, M., Jaffe, E.S., Giardina, S., Waldmann, T.A. & Pastan, I. (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology, 18, 1622–1636.
49. Kreitman, R.J., Stetler-Stevenson, M., Jaffe, E.S., Conlon, K.C., Steinberg, S.M., Wilson, W.H., Waldmann, T.A. & Pastan, I. (2015) Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clinical Cancer Research, 22, 310–318.
50. Krueger, J.G., Walters, I.B., Miyazawa, M., Gilleaudeau, P., Hakimi, J., Light, S., Sherr, A. & Gottlieb, A.B. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. Journal of the American Academy of Dermatology, 43, 448–458.
51. Ladenstein, R., Poetschger, U., Gray, J., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Elliott, M., Michon, J.M., Owens, C., Trahair, T., Chan, G.C.F., Ruud, E., Schroeder, E., Popovic, M.B., Glogova, E., Schreier, G., Loibner, H. & Lode, H.N. 2016. Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial). Journal of Clinical Oncology, 34, 10500.
52. Lee, N.R., Song, E.K., Jang, K.Y., Choi, H.N., Moon, W.S., Kwon, K., Lee, J.H., Yim, C.Y. & Kwak, J.Y. (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leukaemia & Lymphoma, 49, 247–256.
53. Lee, J.W., Chen, Z., Geng, H., Xiao, G., Park, G., Parekh, S., Kornblau, S.M., Melnick, A., Abbas, A., Paietta, E. & Muschen, M. 2015. CD25 (IL2RA) orchestrates negative feedback control and stabilizes oncogenic signaling strength in acute lymphoblastic leukemia. [Poster]. Blood, 126, 1434.
54. Levin, A.M., Bates, D.L., Ring, A.M., Krieg, C., Lin, J.T., Su, L., Moraga, I., Raeber, M.E., Bowman, G.R., Novick, P., Pande, V.S., Fathman, C.G., Boyman, O. & Garcia, K.C. (2012) Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature, 484, 529–533.
55. Li, H., Zhou, H., Zhang, Q., Zhao, S., Zhang, Y., Wang, Y., Liu, J., Song, Y., Yu, X. & Yu, Y. (2013) Functional polymorphism rs7072793 C > T affect individual susceptibility to breast cancer by modulating CD25 transcription activity. Molecular Carcinogenesis, 52, 370–376.
56. + regulatory T cells and their functional regulation. Cellular & Molecular Immunology, 12, 558–565.
57. Lim, K.H., Tefferi, A., Lasho, T.L., Finke, C., Patnaik, M., Butterfield, J.H., McClure, R.F., Li, C.Y. & Pardanani, A. (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, 113, 5727–5736.
58. Liparoto, S.F. & Ciardelli, T.L. (1999) Biosensor analysis of the interleukin-2 receptor complex. Journal of Molecular Recognition, 12, 316–321.
59. Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J.S., Melamud, E., Wang, F., Diesl, V., Follettie, M.T., Musto, S., Lam, M.H., Hu, W., Charati, M.B., Khandke, K., Kim, K.S., Cinque, M., Lucas, J., Graziani, E., Maderna, A., O'Donnell, C.J., Arndt, K.T. & Gerber, H.P. (2015) Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Molecular Cancer Therapeutics, 14, 952–963.
60. Lowe, C.E., Cooper, J.D., Brusko, T., Walker, N.M., Smyth, D.J., Bailey, R., Bourget, K., Plagnol, V., Field, S., Atkinson, M., Clayton, D.G., Wicker, L.S. & Todd, J.A. (2007) Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genetics, 39, 1074–1082.
61. Madhumathi, J., Devilakshmi, S., Sridevi, S. & Verma, R.S. (2016) Immunotoxin therapy for hematologic malignancies: where are we heading? Drug Discovery Today, 21, 325–332.
62. Maggiano, N., Colotta, F., Castellino, F., Ricci, R., Valitutti, S., Larocca, L.M. & Musiani, P. (1990) Interleukin-2 receptor expression in human mast cells and basophils. International Archives of Allergy and Applied Immunology, 91, 8–14.
63. Malek, T.R. (2008) The biology of interleukin-2. Annual Review of Immunology, 26, 453–479.
64. Maruyama, D., Tobinai, K., Ando, K., Ohmachi, K., Ogura, M., Uchida, T., Nakanishi, T. & Namiki, M. (2015) Phase I study of E7777, a diphtheria toxin fragment-interleukin-2 fusion protein, in Japanese patients with relapsed or refractory peripheral and cutaneous T-cell lymphoma. Blood, 126, 2724.
65. Mohammed, Z.M., Going, J.J., Edwards, J., Elsberger, B. & McMillan, D.C. (2013) The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 109, 1676–1684.
66. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., Neri, T.M. & Ardizzoni, A. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. Journal of Clinical Oncology, 26, 1789–1796.
67. Nakase, K., Kita, K., Shirakawa, S., Tanaka, I. & Tsudo, M. (1994a) Induction of cell surface interleukin 2 receptor alpha chain expression on non-T lymphoid leukemia cells. Leukemia Research, 18, 855–859.
68. Nakase, K., Kita, K., Nasu, K., Ueda, T., Tanaka, I., Shirakawa, S. & Tsudo, M. (1994b) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. American Journal of Hematology, 46, 179–183.
69. Nakase, K., Tsuji, K., Tamaki, S., Tanigawa, M., Ikeda, T., Miyanishi, E. & Shiku, H. (2005) Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detection and Prevention, 29, 256–259.
70. Ni, X., Jorgensen, J.L., Goswami, M., Challagundla, P., Decker, W.K., Kim, Y.H. & Duvic, M.A. (2015) Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clinical Cancer Research, 21, 274–285.
71. Nikaido, T., Shimizu, A., Ishida, N., Sabe, H., Teshigawara, K., Maeda, M., Uchiyama, T., Yodoi, J. & Honjo, T. (1984) Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature, 311, 631–635.
72. Nishikawa, H. & Sakaguchi, S. (2014) Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 27, 1–7.
73. + helper T cell responses in cancer patients. Blood, 106, 1008–1011.
74. Oflazoglu, E., Kissler, K.M., Sievers, E.L., Grewal, I.S. & Gerber, H.P. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. British Journal of Haematology, 142, 69–73.
75. Olkhanud, P.B., Damdinsuren, B., Bodogai, M., Gress, R.E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R.P. & Biragyn, A. (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Research, 71, 3505–3515.
76. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P. & Nichols, J. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology, 19, 376–388.
77. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. & Nakayama, E. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Research, 59, 3128–3133.
78. Paietta, E., Racevskis, J., Neuberg, D., Rowe, J.M., Goldstone, A.H. & Wiernik, P.H. (1997) Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia, 11, 1887–1890.
79. Palanca-Wessels, M.C. & Press, O.W. (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood, 123, 2293–2301.
80. Pfender, N. & Martin, R. (2014) Daclizumab (anti-CD25) in multiple sclerosis. Experimental Neurology, 26, 44–51.
81. Phillips, G., Guo, S., Bender, R., Havrdova, E., Proskorovsky, I. & Vollmer, T. (2016) Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: results from the SELECT trial. Multiple Sclerosis and Related Disorders, 6, 66–72.
82. Powell, D.J., Felipe-Silva, A., Merino, M.J., Ahmadzadeh, M., Allen, T., Levy, C., White, D.E., Mavroukakis, S., Kreitman, R.J., Rosenberg, S.A. & Pastan, I. (2007) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. The Journal of Immunology, 179, 4919–4928.
83. Rabinovich, G.A., Gabrilovich, D. & Sotomayor, E.M. (2007) Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 25, 267–296.
84. Raimondi, G., Turner, M.S., Thomson, A.W. & Morel, P.A. (2007) Naturally occurring regulatory T cells: recent insights in health and disease. Critical Reviews in Immunology, 27, 61–95.
85. Rickert, M., Boulanger, M.J., Goriatcheva, N. & Garcia, K.C. (2004) Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. Journal of Molecular Biology, 339, 1115–1128.
86. Rickert, M., Wang, X., Boulanger, M.J., Goriatcheva, N. & Garcia, K.C. (2005) The structure of interleukin-2 complexed with its alpha receptor. Science, 308, 1477–1480.
87. Riedel, D., Lindemann, A., Brach, M., Mertelsmann, R. & Herrmann, F. (1990) Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology, 70, 258–261.
88. Roncarolo, M.G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K. & Levings, M.K. (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 212, 28–50.
89. Rubin, L.A., Kurman, C.C., Fritz, M.E., Biddison, W.E., Boutin, B., Yarchoan, R. & Nelson, D.L. (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. The Journal of Immunology, 135, 3172–3177.
90. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., Ozawa, H., Wake, A., Taniguchi, S., Shultz, L.D., Ohara, O. & Ishikawa, F. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Science Translational Medicine, 2, 17ra9.
91. Sakai, A. & Yoshida, N. (2014) The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas. Journal of Clinical and Experimental Hematopathology, 54, 49–57.
92. San Miguel, J.F., Vidriales, M.B., Ocio, E., Mateo, G., Sanchez-Guijo, F., Sanchez, M.L., Escribano, L., Barez, A., Moro, M.J., Hernandez, J., Aguilera, C., Cuello, R., Garcia-Frade, J., Lopez, R., Portero, J. & Orfao, A. (2003) Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Seminars in Oncology, 30, 187–195.
93. Schnell, R., Vitetta, E., Schindler, J., Barth, S., Winkler, U., Borchmann, P., Hansmann, M.L., Diehl, V., Ghetie, V. & Engert, A. (1998) Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leukaemia & Lymphoma, 30, 525–537.
94. Schwartz, M., Zhang, Y. & Rosenblatt, J.D. (2016) B cell regulation of the anti-tumor response and role in carcinogenesis. Journal for Immunotherapy of Cancer, 4, 40.
95. Smith, F.O., Downey, S.G., Klapper, J.A., Yang, J.C., Sherry, R.M., Royal, R.E., Kammula, U.S., Hughes, M.S., Restifo, N.P., Levy, C.L., White, D.E., Steinberg, S.M. & Rosenberg, S.A. (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clinical Cancer Research, 14, 5610–5618.
96. Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Li, Y., Kurreeman, F.A., Zhernakova, A., Hinks, A., Guiducci, C., Chen, R., Alfredsson, L., Amos, C.I., Ardlie, K.G., Barton, A., Bowes, J., Brouwer, E., Burtt, N.P., Catanese, J.J., Coblyn, J., Coenen, M.J., Costenbader, K.H., Criswell, L.A., Crusius, J.B., Cui, J., De Bakker, P.I., De Jager, P.L., Ding, B., Emery, P., Flynn, E., Harrison, P., Hocking, L.J., Huizinga, T.W., Kastner, D.L., Ke, X., Lee, A.T., Liu, X., Martin, P., Morgan, A.W., Padyukov, L., Posthumus, M.D., Radstake, T.R., Reid, D.M., Seielstad, M., Seldin, M.F., Shadick, N.A., Steer, S., Tak, P.P., Thomson, W., Van Der Helm-Van Mil, A.H., Van Der Horst-Bruinsma, I.E., Van Der Schoot, C.E., Van Riel, P.L., Weinblatt, M.E., Wilson, A.G., Wolbink, G.J., Wordsworth, B.P., Wijmenga, C., Karlson, E.W., Toes, R.E., De Vries, N., Begovich, A.B., Worthington, J., Siminovitch, K.A., Gregersen, P.K., Klareskog, L. & Plenge, R.M. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 42, 508–514.
97. Strauchen, J.A. & Breakstone, B.A. (1987) IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. American Journal of Pathology, 126, 506–512.
98. Taniguchi, T. & Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell, 73, 5–8.
99. Tarhini, A.A., Edington, H., Butterfield, L.H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., Rao, U.N. & Kirkwood, J.M. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE, 9, e87705.
100. Tartour, E., Mosseri, V., Jouffroy, T., Deneux, L., Jaulerry, C., Brunin, F., Fridman, W.H. & Rodriguez, J. (2001) Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet, 357, 1263–1264.
101. Taylor, R.J., Chan, S.L., Wood, A., Voskens, C.J., Wolf, J.S., Lin, W., Chapoval, A., Schulze, D.H., Tian, G. & Strome, S.E. (2009) FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunology, Immunotherapy, 58, 997–1006.
102. Teege, S., Hann, A., Miksiewicz, M., Macmillan, C., Rissiek, B., Buck, F., Menzel, S., Nissen, M., Bannas, P., Haag, F., Boyer, O., Seman, M., Adriouch, S. & Koch-Nolte, F. (2015) Tuning IL-2 signaling by ADP-ribosylation of CD25. Scientific Reports, 5, 8959.
103. Terwijn, M., Feller, N., van Rhenen, A., Kelder, A., Westra, G., Zweegman, S., Ossenkoppele, G. & Schuurhuis, G.J. (2009) Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45, 1692–1699.
104. Tesch, H., Gunther, A., Abts, H., Jucker, M., Klein, S., Krueger, G.R. & Diehl, V. (1993) Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. American Journal of Pathology, 142, 1714–1720.
105. Tiberghien, A.C., Levy, J.N., Masterson, L.A., Patel, N.V., Adams, L.R., Corbett, S., Williams, D.G., Hartley, J.A. & Howard, P.W. (2016) Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Medicinal Chemistry Letters, 7, 983–987.
106. Tkaczuk, J., Yu, C.L., Baksh, S., Milford, E.L., Carpenter, C.B., Burakoff, S.J. & McKay, D.B. (2002) Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling. American Journal of Transplantation, 2, 31–40.
107. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica, 93, 193–200.
108. Uchiyama, T., Broder, S. & Waldmann, T.A. (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. The Journal of Immunology, 126, 1393–1397.
109. Waldmann, T.A. (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Journal of Clinical Immunology, 27, 1–18.
110. Waldmann, T.A., Goldman, C.K., Robb, R.J., Depper, J.M., Leonard, W.J., Sharrow, S.O., Bongiovanni, K.F., Korsmeyer, S.J. & Greene, W.C. (1984) Expression of interleukin 2 receptors on activated human B cells. Journal of Experimental Medicine, 160, 1450–1466.
111. Waldmann, T.A., Goldman, C.K., Bongiovanni, K.F., Sharrow, S.O., Davey, M.P., Cease, K.B., Greenberg, S.J. & Longo, D.L. (1988) Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood, 72, 1805–1816.
112. Waldmann, T.A., White, J.D., Goldman, C.K., Top, L., Grant, A., Bamford, R., Roessler, E., Horak, I.D., Zaknoen, S. & Kasten-Sportes, C. (1993) The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood, 82, 1701–1712.
113. Waldmann, T.A., White, J.D., Carrasquillo, J.A., Reynolds, J.C., Paik, C.H., Gansow, O.A., Brechbiel, M.W., Jaffe, E.S., Fleisher, T.A., Goldman, C.K., Top, L.E., Bamford, R., Zaknoen, E., Roessler, E., Kasten-Sportes, C., England, R., Litou, H., Johnson, J.A., Jackson-White, T., Manns, A., Hanchard, B., Junghans, R.P. & Nelson, D.L. (1995) Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86, 4063–4075.
114. + Tregs. The Journal of Clinical Investigation, 116, 2521–2531.
115. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.Y., Mendrzyk, R., Hilf, N., Schoor, O., Fritsche, J., Mahr, A., Maurer, D., Vass, V., Trautwein, C., Lewandrowski, P., Flohr, C., Pohla, H., Stanczak, J.J., Bronte, V., Mandruzzato, S., Biedermann, T., Pawelec, G., Derhovanessian, E., Yamagishi, H., Miki, T., Hongo, F., Takaha, N., Hirakawa, K., Tanaka, H., Stevanovic, S., Frisch, J., Mayer-Mokler, A., Kirner, A., Rammensee, H.G., Reinhardt, C. & Singh-Jasuja, H. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 18, 1254–1261.
116. Wang, L.S., Chow, K.C., Li, W.Y., Liu, C.C., Wu, Y.C. & Huang, M.H. (2000) Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clinical Cancer Research, 6, 1445–1451.
117. Wayne, A.S., Fitzgerald, D.J., Kreitman, R.J. & Pastan, I. (2014) Immunotoxins for leukemia. Blood, 123, 2470–2477.
118. Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 3940–3947.
119. Yamauchi, T., Matsuda, Y., Takai, M., Tasaki, T., Tai, K., Hosono, N., Negoro, E., Ikegaya, S., Takagi, K., Kishi, S., Yoshida, A., Urasaki, Y., Iwasaki, H. & Ueda, T. (2012) Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Research, 32, 5051–5057.
120. Yang, H., Wang, J., Du, J., Zhong, C., Zhang, D., Guo, H., Guo, Y. & Ding, J. (2010) Structural basis of immunosuppression by the therapeutic antibody daclizumab. Cell Research, 20, 1361–1371.
121. Yano, T., Fukuyama, Y., Yokoyama, H., Takai, E., Tanaka, Y., Asoh, H. & Ichinose, Y. (1996) Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer, 16, 13–19.
122. Yoshida, N., Oda, M., Kuroda, Y., Katayama, Y., Okikawa, Y., Masunari, T., Fujiwara, M., Nishisaka, T., Sasaki, N., Sadahira, Y., Mihara, K., Asaoku, H., Matsui, H., Seto, M., Kimura, A., Arihiro, K. & Sakai, A. (2013) Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS ONE, 8, e78730.
123. Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., Shimada, H., Grupp, S.A., Seeger, R., Reynolds, C.P., Buxton, A., Reisfeld, R.A., Gillies, S.D., Cohn, S.L., Maris, J.M. & Sondel, P.M. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. New England Journal of Medicine, 363, 1324–1334.
124. Zeiser, R. & Negrin, R.S. (2008) Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle, 7, 458–462.
125. + T cells. Blood, 111, 453–462.